Group 1 - The company, 纳微科技 (Nanwei Technology), has stated that it currently does not have any revenue from the micro-sphere applications mentioned by investors [1]

Market Performance - The chemical pharmaceutical sector increased by 1.41% on February 3, with Yiming Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Top Gainers in Chemical Pharmaceutical Sector - Yiming Pharmaceutical (002826) closed at 20.98, up 9.27% with a trading volume of 269,200 shares and a transaction value of 559 million [1] - Yuandong Biological (688513) closed at 68.90, up 8.85% with a trading volume of 64,600 shares [1] - Nami Technology (688690) closed at 29.00, up 7.01% with a trading volume of 93,900 shares and a transaction value of 265 million [1] - Lianhuan Pharmaceutical (600513) closed at 20.15, up 5.94% with a trading volume of 162,200 shares and a transaction value of 323 million [1] Top Losers in Chemical Pharmaceutical Sector - Shuangbi Pharmaceutical (002038) closed at 6.41, down 7.10% with a trading volume of 801,300 shares and a transaction value of 511 million [2] - Haizhi Pharmaceutical (002653) closed at 47.50, down 5.47% with a trading volume of 90,200 shares and a transaction value of 430 million [2] - Nuo Cheng Jianhua (688428) closed at 21.13, down 3.78% with a trading volume of 163,500 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 42.01 million from institutional investors, while retail investors saw a net inflow of 651 million [2] - The main capital inflow was observed in Yiming Pharmaceutical with 58.98 million, while it faced a net outflow of 58.77 million from retail investors [3] - Other notable inflows included Guangsheng Tang (300436) with 14.8 million from main capital, while it faced a net outflow of 95.56 million from retail investors [3]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Group 1 - The core business of Suzhou Nanwei Technology Co., Ltd. involves the research, large-scale production, sales, and application services of high-performance nano microsphere materials, serving clients in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [2] - As of September 30, 2025, Nanwei Technology achieved a revenue of 671 million yuan, representing a year-on-year growth of 22.01%, and a net profit attributable to shareholders of 108 million yuan, with a significant increase of 156.56% [2] - The company has distributed a total of 115 million yuan in dividends since its A-share listing, with 86.84 million yuan distributed over the past three years [3] Group 2 - On January 29, 2025, Nanwei Technology's stock price increased by 1.94%, with a trading volume of 233 million yuan [1] - The financing data on January 29 indicates that Nanwei Technology had a net financing buy of -12.20 million yuan, with a total financing balance of 347 million yuan, accounting for 3.01% of its market capitalization [1] - The short selling data shows that on January 29, 800 shares were repaid and 500 shares were sold short, with a short selling balance of 1.35 million yuan, which is above the 90th percentile level over the past year [1]

证券日报网讯1月29日，纳微科技在互动平台回答投资者提问时表示，公司通过完善海外营销体系、加 强海外销售力量及与战略合作伙伴合作，推动海外业务快速增长。目前欧洲市场由国际业务团队直接提 供应用技术服务和直销供应，2025年度国际业务收入约8400万元，同比增长约79%，其中来自欧盟国家 的药物应用项目收入亦快速增长，但在公司整体收入中占比不高。 ...

本文源自：市场资讯 作者：公告君 有投资者在互动平台向纳微科技提问："从海外业务来源地区看，已有欧盟国家的药物应用项目，请问 欧盟地区业务收入在公司整体营业收入中的占比大致为多少？此外，公司对欧盟市场的销售主要通过哪 种方式实现？是以境内主体直接向欧盟客户出口为主，还是通过在欧盟国家设立的子公司进行销售，或 通过第三方贸易商、代理商转销至欧盟市场？" 针对上述提问，纳微科技回应称："尊敬的投资者，您好！公司通过完善海外营销体系，加强海外销售 力量，增加与战略合作伙伴的合作等措施，推动海外业务快速增长。目前，欧洲市场的业务拓展采取公 司直接提供应用技术服务和直销供应的方式实现，主要由公司的国际业务团队负责。公司在《2025年年 度业绩预告的自愿性披露公告》中披露，2025年度公司实现国际业务收入约8,400万元，同比增长约 79%，其中，来自欧盟国家的药物应用项目收入也实现快速增长，但在公司整体收入中的占比不高。谢 谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

（文章来源：证券日报） 证券日报网讯 1月28日，纳微科技在互动平台回答投资者提问时表示，公司重视人工智能技术的应用， 目前在使用人工智能辅助产品设计、工艺开发等方面已有场景探索和应用布局。 ...

北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2026 年员工持股计划的 法律意见书 2026 年员工持股计划的 法律意见书 二〇二六年一月 法律意见书 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 致苏州纳微科技股份有限公司： 北京市中伦（上海）律师事务所（以下简称"本所"）接受苏州纳微科技股份 有限公司（以下简称"纳微科技"或"公司"）的委托，就公司 2026 年员工持股计 划（以下简称"本次员工持股计划"）相关事宜担任法律顾问。本所律师根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下 简称《证券法》）、中国证券监督管理委员会（以下简称"中国证监会"）发布的《关 于上市公司实施员工持股计划试点的指导意见（2025 修订）》（以下简称《指导 意见》）、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作 （2025 年 5 月修订）》（以下简称《自律监管指引第 1 号》）等有关法律、法规和 规范性文件和《苏州纳微科技股份有限公司章程》（以下简称"《公司章程》"）的 规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对纳微科技 ...

Core Viewpoint - Nanwei Technology is revolutionizing the global high-end materials industry through original innovation and industrialization breakthroughs in nanosphere technology, marking a significant shift for China's new materials sector from laboratory to global market [1][2]. Group 1: Original Innovation and Industrialization - The strategic significance of nanosphere materials is highlighted, as they are essential for the production of biopharmaceuticals and electronics [2]. - The company was founded in 2007 in Suzhou, focusing on high-performance nanosphere materials, addressing a gap in the domestic market where over 90% of chromatography fillers were imported [2][3]. - The initial challenges included a failed technology route that required a complete overhaul of the technical system, which took an additional five years to resolve [3]. Group 2: Product Applications and Market Expansion - Nanwei's products are primarily used in biopharmaceutical separation and purification, as well as in environmental analysis and diagnostics [4]. - The company has significantly reduced production time and costs compared to competitors, exemplified by a six-day production cycle for LCD screen microbeads versus six months for Japanese firms [4]. - New membrane materials developed for organic solvent filtration have filled a global technology gap, allowing for energy-efficient recycling processes [4][5]. Group 3: Industry Collaboration and Future Plans - Nanwei has established a 42,000 square meter R&D and production base in Suzhou and an 18,000 square meter facility in Changshu for large-scale production [6]. - The company anticipates a revenue of 918 million to 930 million yuan in 2025, with a net profit increase of 54.51% to 75.03% [6]. - A unique collaboration model with academic institutions has been developed to address industrial pain points, resulting in over a hundred patent applications [6]. - Future plans include building a systematic platform for high-end materials and expanding into international markets to promote domestic original innovation technologies globally [7].

Core Viewpoint - Nanwei Technology is revolutionizing the global high-end materials industry through original innovation and industrialization breakthroughs in the field of nano microspheres, which are crucial for biopharmaceuticals and analytical testing [1][2]. Group 1: Company Background and Innovation - Nanwei Technology was founded in 2007 in Suzhou, focusing on the research and application of high-performance nano microsphere materials [1]. - The company aims to fill the industrial gap in nano microspheres, which are essential for biopharmaceutical production and have been dominated by foreign companies [2]. - The founder, Jiang Biwang, emphasizes the importance of original innovation to establish a foothold in the nano microsphere market [2]. Group 2: Technological Advancements - Nanwei Technology has developed a new manufacturing technique using the "seed method" to produce uniform microspheres, significantly reducing production costs and time compared to traditional methods [3]. - The company launched its self-developed monodisperse silica chromatography filler in 2016, filling a domestic technological gap [3]. Group 3: Market Applications and Expansion - The microspheres produced by Nanwei are used in various fields, including biopharmaceutical separation and purification, environmental analysis, and flat panel displays [3]. - The company has demonstrated that its products can outperform competitors, such as reducing the amount of filler needed for biopharmaceutical production, thus enhancing efficiency and reducing solvent consumption [3]. Group 4: Future Growth and Financial Projections - Nanwei Technology plans to achieve an estimated revenue of 918 million to 930 million yuan by 2025, representing a year-on-year growth of 17.32% to 18.86% [4]. - The projected net profit for the same period is expected to be between 128 million to 145 million yuan, indicating a significant increase of 54.51% to 75.03% [4]. Group 5: Collaborative Ecosystem - The company has established a unique collaboration model with academic institutions to address industrial pain points while leveraging their expertise in single-point technological breakthroughs [5]. - Nanwei Technology has applied for over a hundred patents, building a robust intellectual property system to support its innovations [5].